Literature DB >> 16537560

Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5.

Thomas C Sroka1, Michael E Pennington, Anne E Cress.   

Abstract

Cell motility is partially dependent on interactions between the integrins and the extracellular matrix. Our previous studies have identified synthetic D-amino acid cell adhesion peptides using a combinatorial screening approach. In this study, we demonstrate that HYD1 (kikmviswkg) completely blocks random haptotactic migration and inhibits invasion of prostate carcinoma cells on laminin-5. This effect is adhesion independent and reversible. The inhibition of migration by HYD1 involves a dramatic remodeling of the actin cytoskeleton resulting in increased stress fiber formation and actin colocalization with cortactin at the cell membrane. HYD1 interacts with alpha6beta1 (not alpha6beta4) and alpha3beta1 integrins and surprisingly elevates laminin-5-dependent intracellular signals including focal adhesion kinase, mitogen-activated protein kinase kinase and extracellular signal-regulated kinase. HYD1 does not contain a previously characterized binding sequence for integrins. A scrambled derivative of HYD1, called HYDS (wiksmkivkg), does not interact with the alpha6 or alpha3 integrin subunits and is not biologically active. Taken together, these results indicate that HYD1 is a biologically active integrin-targeting peptide that reversibly inhibits tumor cell migration on laminin-5 and uncouples phosphotyrosine signaling from cytoskeletal-dependent migration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537560      PMCID: PMC4069207          DOI: 10.1093/carcin/bgl005

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  57 in total

1.  Culture conditions affect expression of the alpha 6 beta 4 integrin associated with aggressive behavior in head and neck cancer.

Authors:  T E Carey; L Laurikainen; A Ptok; T Reinke; K Linder; T S Nair; C Marcelo
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

2.  Migration of breast epithelial cells on Laminin-5: differential role of integrins in normal and transformed cell types.

Authors:  G E Plopper; S Z Domanico; V Cirulli; W B Kiosses; V Quaranta
Journal:  Breast Cancer Res Treat       Date:  1998-09       Impact factor: 4.872

3.  Activation of beta1 integrin signaling stimulates tyrosine phosphorylation of p190RhoGAP and membrane-protrusive activities at invadopodia.

Authors:  H Nakahara; S C Mueller; M Nomizu; Y Yamada; Y Yeh; W T Chen
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

4.  Novel peptide ligands for integrin alpha 6 beta 1 selected from a phage display library.

Authors:  O Murayama; H Nishida; K Sekiguchi
Journal:  J Biochem       Date:  1996-08       Impact factor: 3.387

5.  Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells.

Authors:  J K Slack; R B Adams; J D Rovin; E A Bissonette; C E Stoker; J T Parsons
Journal:  Oncogene       Date:  2001-03-08       Impact factor: 9.867

6.  Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src.

Authors:  V J Fincham; M James; M C Frame; S J Winder
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

7.  Laminin-10/11 and fibronectin differentially regulate integrin-dependent Rho and Rac activation via p130(Cas)-CrkII-DOCK180 pathway.

Authors:  J Gu; Y Sumida; N Sanzen; K Sekiguchi
Journal:  J Biol Chem       Date:  2001-05-21       Impact factor: 5.157

8.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.

Authors:  Erik Sahai; Christopher J Marshall
Journal:  Nat Cell Biol       Date:  2003-08       Impact factor: 28.824

9.  Identification of a potent peptide antagonist to an active laminin-1 sequence that blocks angiogenesis and tumor growth.

Authors:  M Lourdes Ponce; Suguru Hibino; Agata M Lebioda; Mayumi Mochizuki; Motoyoshi Nomizu; Hynda K Kleinman
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

10.  Synthetic peptides from the carboxy-terminal globular domain of the A chain of laminin: their ability to promote cell adhesion and neurite outgrowth, and interact with heparin and the beta 1 integrin subunit.

Authors:  A P Skubitz; P C Letourneau; E Wayner; L T Furcht
Journal:  J Cell Biol       Date:  1991-11       Impact factor: 10.539

View more
  17 in total

Review 1.  Integrins as therapeutic targets: lessons and opportunities.

Authors:  Dermot Cox; Marian Brennan; Niamh Moran
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

Review 2.  Laminin-332-integrin interaction: a target for cancer therapy?

Authors:  Daisuke Tsuruta; Hiromi Kobayashi; Hisayoshi Imanishi; Koji Sugawara; Masamitsu Ishii; Jonathan C R Jones
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 3.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

4.  Cell-penetrating peptides with intracellular actin-remodeling activity in malignant fibroblasts.

Authors:  Diane Delaroche; François-Xavier Cantrelle; Frédéric Subra; Carine Van Heijenoort; Eric Guittet; Chen-Yu Jiao; Laurent Blanchoin; Gérard Chassaing; Solange Lavielle; Christian Auclair; Sandrine Sagan
Journal:  J Biol Chem       Date:  2009-12-27       Impact factor: 5.157

5.  Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.

Authors:  Isis C Sroka; Cynthia P Sandoval; Harsharon Chopra; Jaime M C Gard; Sangita C Pawar; Anne E Cress
Journal:  Mol Cancer Res       Date:  2011-08-08       Impact factor: 5.852

6.  Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.

Authors:  Michael F Emmons; Anthony W Gebhard; Rajesh R Nair; Rachid Baz; Mark L McLaughlin; Anne E Cress; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2011-10-06       Impact factor: 6.261

7.  Dephosphorylation of D-peptide derivatives to form biofunctional, supramolecular nanofibers/hydrogels and their potential applications for intracellular imaging and intratumoral chemotherapy.

Authors:  Jiayang Li; Yuan Gao; Yi Kuang; Junfeng Shi; Xuewen Du; Jie Zhou; Huaimin Wang; Zhimou Yang; Bing Xu
Journal:  J Am Chem Soc       Date:  2013-06-21       Impact factor: 15.419

8.  MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.

Authors:  Anthony W Gebhard; Priyesh Jain; Rajesh R Nair; Michael F Emmons; Raul F Argilagos; John M Koomen; Mark L McLaughlin; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2013-09-18       Impact factor: 6.261

9.  A D-amino acid containing peptide as a potent, noncovalent inhibitor of α5β1 integrin in human prostate cancer invasion and lung colonization.

Authors:  Donna M Veine; Hongren Yao; Daniel R Stafford; Kevin S Fay; Donna L Livant
Journal:  Clin Exp Metastasis       Date:  2014-01-25       Impact factor: 5.150

Review 10.  Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.

Authors:  Nagaraju Anreddy; Lori A Hazlehurst
Journal:  J Cell Biochem       Date:  2016-06-21       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.